Matsubara K, Yamamoto H, Okita R, Otani S, Watanabe M, Ueno T
Ann Thorac Surg Short Rep. 2025; 2(4):603-607.
PMID: 39790604
PMC: 11708677.
DOI: 10.1016/j.atssr.2024.06.026.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J
Sci Rep. 2025; 15(1):72.
PMID: 39747852
PMC: 11696502.
DOI: 10.1038/s41598-024-78539-4.
An S, Eo W, Kim D, Lee S
J Cancer. 2024; 15(19):6185-6195.
PMID: 39513125
PMC: 11540506.
DOI: 10.7150/jca.101320.
Zhao L, Cui M, Yang S, Zhou H, Li M
J Inflamm Res. 2024; 17:6905-6916.
PMID: 39372594
PMC: 11451455.
DOI: 10.2147/JIR.S474201.
Luo B, Zhang Y, Zhu X, Ji T, Wu K, Sun D
Langenbecks Arch Surg. 2024; 409(1):223.
PMID: 39023651
DOI: 10.1007/s00423-024-03423-8.
Prognostic impact of preoperative nutritional and immune inflammatory parameters on liver cancer.
Bae S
World J Gastrointest Surg. 2024; 16(2):266-269.
PMID: 38463370
PMC: 10921218.
DOI: 10.4240/wjgs.v16.i2.266.
Predicting outcomes of Lung Cancer using the modified glasgow prognostic score: A systematic review and meta-analysis.
Min Y, Li X, Chen H, Xu Y, Lan G
Pak J Med Sci. 2024; 40(3Part-II):534-543.
PMID: 38356845
PMC: 10862437.
DOI: 10.12669/pjms.40.3.8397.
Predictive value of perioperative procalcitonin, C reactive protein and high-sensitivity C reactive protein for the risk of postoperative complications after non-cardiac surgery in elderly patients: a nested case-control study.
Chen Y, Zhao Y, Liu J, Teng Y, Ou M, Hao X
BMJ Open. 2023; 13(10):e071464.
PMID: 37832985
PMC: 10583102.
DOI: 10.1136/bmjopen-2022-071464.
Prognostic Value of Combined Hematological/Biochemical Indexes and Tumor Clinicopathologic Features in Colorectal Cancer Patients-A Pilot Single Center Study.
Cuk V, Karamarkovic A, Juloski J, Arbutina D, Radulovic R, Milic L
Cancers (Basel). 2023; 15(6).
PMID: 36980648
PMC: 10046459.
DOI: 10.3390/cancers15061761.
The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment.
Aguilar-Cazares D, Chavez-Dominguez R, Marroquin-Mucino M, Perez-Medina M, Benito-Lopez J, Camarena A
Front Endocrinol (Lausanne). 2022; 13:929572.
PMID: 36072935
PMC: 9441602.
DOI: 10.3389/fendo.2022.929572.
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K
Hepatol Int. 2022; 16(5):1150-1160.
PMID: 35749019
DOI: 10.1007/s12072-022-10358-z.
C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J
Sci Rep. 2022; 12(1):8421.
PMID: 35589772
PMC: 9120140.
DOI: 10.1038/s41598-022-12058-y.
Systemic inflammatory response predicts poor prognoses in Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma with transarterial chemoembolization: a prospective study.
Huang Z, Lu W, Yu N, Yang G, Xu H, Liu H
Transl Cancer Res. 2022; 8(7):2552-2563.
PMID: 35117012
PMC: 8798496.
DOI: 10.21037/tcr.2019.10.18.
Prognostic Value of C-Reactive Protein, Glasgow Prognostic Score, and C-Reactive Protein-to-Albumin Ratio in Colorectal Cancer.
Zhou J, Wei W, Hou H, Ning S, Li J, Huang B
Front Cell Dev Biol. 2021; 9:637650.
PMID: 34765598
PMC: 8577830.
DOI: 10.3389/fcell.2021.637650.
Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis.
Song X, Zhang H, Yin F, Guo P, Yang X, Liu J
Mediators Inflamm. 2021; 2021:3456629.
PMID: 34720749
PMC: 8553478.
DOI: 10.1155/2021/3456629.
Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: a systematic review and meta-analysis.
Jiang Y, Xu D, Song H, Qiu B, Tian D, Li Z
BMJ Open. 2021; 11(9):e048324.
PMID: 34593492
PMC: 8487212.
DOI: 10.1136/bmjopen-2020-048324.
Clinical significance of C-Reactive Protein to Lymphocyte Count Ratio as a prognostic factor for Survival in Non-small Cell Lung Cancer Patients undergoing Curative Surgical Resection.
Hwang J, Hur J, Eo W, An S, Kim D, Lee S
J Cancer. 2021; 12(15):4497-4504.
PMID: 34149913
PMC: 8210557.
DOI: 10.7150/jca.58094.
C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.
Hayashi T, Shibata M, Oe S, Miyagawa K, Honma Y, Harada M
PLoS One. 2020; 15(12):e0244370.
PMID: 33351844
PMC: 7755182.
DOI: 10.1371/journal.pone.0244370.
C-reactive Protein/Albumin Ratio and Acute Kidney Injury after Radical Cystectomy among Elderly Patients: A Propensity Score-Matched Analysis.
Yu J, Park J, Ha S, Hwang J, Kim Y
Dis Markers. 2020; 2020:8818445.
PMID: 33193910
PMC: 7641682.
DOI: 10.1155/2020/8818445.
C-reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma.
Matsumoto T, Itoh S, Yoshizumi T, Kurihara T, Yoshiya S, Mano Y
BJS Open. 2020; .
PMID: 32959537
PMC: 7709369.
DOI: 10.1002/bjs5.50348.